Biotech: Page 78
-
Permission granted by Relay Therapeutics
Relay’s targeted cancer drug could be safer than its competitors. Is it more effective?
Initial study results for Relay's experimental treatment offer some support for the biotech's protein motion technology, but raise some questions, too.
By Ned Pagliarulo • Oct. 8, 2021 -
Maddie Meyer via Getty Images
Under pressure to share technology, Moderna to build vaccine factory in Africa
The biotech company expects to make its coronavirus vaccine and mRNA shots for other diseases at the planned plant, into which it will invest $500 million.
By Kristin Jensen • Oct. 7, 2021 -
Explore the Trendlineâž”
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Permission granted by Intergalactic Therapeutics
Intergalactic Therapeutics launches with $75M to build a new type of gene therapy
Founded by former Biogen executive Michael Ehlers and backed by Apple Tree Partners, Intergalactic aims to create non-viral gene therapies delivered via an advanced form of electroporation.
By Ned Pagliarulo • Oct. 7, 2021 -
Armed with half a billion dollars, a startup aims to change how brain drugs are made
Neumora Therapeutics launched Thursday with $100 million from Amgen and another $400 million from a long list of venture capital firms, including Arch, which is taking another shot at building a neuroscience company.
By Jacob Bell • Oct. 7, 2021 -
Jeenah Moon via Getty Images
Gene therapy developer gets chance at a comeback with Pfizer deal
Voyager Therapeutics recently scrapped much of its pipeline and replaced top executives. Now, a Pfizer deal on new technology gives investors hope.
By Jonathan Gardner • Oct. 6, 2021 -
Permission granted by Biohaven Pharmaceutical
Biohaven migraine drug sales again top Wall Street forecasts
The neuroscience-focused biotech continues to win market share in a battle with some of the industry's largest companies.
By Kristin Jensen • Oct. 6, 2021 -
Courtesy of Sarepta
Sarepta embarks on late-stage clinical trial of Duchenne gene therapy
Initiation of the Phase 3 trial is an important milestone for the biotech after earlier setbacks, as well as for patients with the inherited muscle disease.
By Shoshana Dubnow • Oct. 4, 2021 -
Kena Betancur via Getty Images
How a busy year for biotech IPOs measures up at the three-quarter mark
Drugmaker initial public offerings could break records set just a year ago. But valuations and stock performance have slipped from historic highs.
By Ben Fidler • Oct. 4, 2021 -
Permission granted by Editas Medicine
After long wait, Editas reveals first data for CRISPR gene editing treatment
Early study results offer some hopeful signs but were difficult to interpret. Shares in the biotech slid by nearly 20% in response on Wednesday.
By Ned Pagliarulo • Sept. 29, 2021 -
FDA lifts hold on GeneTx, Ultragenyx study of Angelman therapy
The hold, which was put in place during the fourth quarter last year, came after five patients in an early trial experienced muscle weakness following treatment.
By Shoshana Dubnow • Sept. 27, 2021 -
Permission granted by Biohaven Pharmaceuticals
Biohaven's pipeline takes a hit as drug for rare neurological disease falls short in trial
After success with the migraine drug Nurtec, Biohaven has been looking to prove the rest of its neuroscience research. Negative Phase 3 results in multiple system atrophy could close off one opportunity.
By Ned Pagliarulo • Sept. 27, 2021 -
iStock.com/PeopleImages
Sponsored by SGSCharged aerosol detection: Chromatographer's magical tool to unravel the invisible in biologics
The discovery and development of next generation therapeutics will drive the availability and use of Biologics to meet the unmet medical needs, never imagined before.
By Yena Patel, Sahil Shah and Bart Byczynski • Sept. 27, 2021 -
Getty / Edited by BioPharma Dive
Bluebird officially asks FDA to approve gene therapy for rare blood disorder
After several delays, Bluebird has completed an application to the agency to get beti-cel cleared as a treatment for beta-thalassemia.
By Jacob Bell • Sept. 22, 2021 -
Incyte eczema drug wins FDA OK, but with safety warning
A topical cream formulation of the drug in Incyte's top-selling product could help the company expand. The black box warning, though, might limit use.
By Kristin Jensen • Sept. 22, 2021 -
Permission granted by Vertex Pharmaceuticals
Deep Dive'This is the time to double down': Top Vertex executives defend research plan as pressure builds
A series of setbacks has led to criticism of the storied biotech's bid to diversify. But Vertex intends to stay the course, its CEO and top scientist say.
By Ben Fidler • Sept. 22, 2021 -
ESMO21: Mirati sets new KRAS bar, AstraZeneca's breast cancer data and Keytruda challengers line up
Mirati's KRAS-blocking drug looks to have an edge over Amgen's, while AstraZeneca and Daiichi reported impressive data for their drug Enhertu.
By Ned Pagliarulo • Updated Sept. 21, 2021 -
Martin Vleck/Shutterstock.com
Sponsored by NuvoloCalibrate and connect your equipment in the cloud
Calibration is too important to do on spreadsheets or paper. See how you can improve your calibration activities with a cloud-based solution.
Sept. 20, 2021 -
Permission granted by Biogen
Biogen says experimental pain drug helps neuropathy patients in mid-stage trial
With Aduhelm approved but struggling to gain traction, Biogen is talking up its pipeline. Mixed trial results, however, may make it challenging to design a larger study that can persuade regulators to approve the pain drug.
By Jonathan Gardner • Sept. 17, 2021 -
Theravance to lay off 75% of employees alongside larger restructuring
The move, which will affect an estimated 270 positions, follows a review by the company's board, and comes just weeks after one of its most advanced drugs failed a key test.
By Jacob Bell • Sept. 15, 2021 -
After talks with FDA, a biotech prepares to submit its closely watched ALS drug
Executives at Amylyx Pharmaceuticals said that based on the agency's recent feedback, they will soon ask for approval of AMX0035 — a change of plans from earlier this year.
By Jacob Bell • Sept. 15, 2021 -
Courtesy of CureVac
CureVac scales back mRNA manufacturing for coronavirus vaccine
The German biotech, which announced disappointing results for its shot in June, said the move was done in response to reduced demand.
By Shoshana Dubnow • Updated Sept. 15, 2021 -
Biotech funder Lightstone raises another $375M for life sciences investing
The venture firm, which previously invested in LocanaBio, Catamaran Bio and Tizona Therapeutics, said its third fund surpassed its target.
By Jacob Bell • Sept. 14, 2021 -
Getty / Edited by BioPharma Dive
Fourth trial volunteer dies in Astellas gene therapy study
The study, which was suspended following three deaths last year, had been restarted in February after Astellas lowered the treatment dose used.
By Ned Pagliarulo • Sept. 14, 2021 -
Permission granted by Biogen
Biogen offered a window into what's holding up Aduhelm. Investors didn't like what they saw.
At Morgan Stanley’s healthcare conference last week, executives detailed how the launch of their Alzheimer’s drug has been slower than expected, due in large part to lingering questions about trial data and insurance coverage.
By Jacob Bell • Sept. 9, 2021 -
Courtesy of Apellis Pharmaceuticals
Apellis eye drug succeeds in one key study, but falls short in its twin
Highly anticipated study results showed divergent outcomes for the biotech's therapy in treating a form of vision loss known as geographic atrophy. Even so, Apellis plans to soon ask for FDA approval.
By Ned Pagliarulo • Updated Sept. 10, 2021
Previous
